Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Oral Midazolam for Perioperative Anxiety Relief of Patients Undergoing Mohs Micrographic Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~- 1 or 2 sites of biopsy-confirmed squamous cell or basal cell carcinomas limited to head and neck regions~Inclusion Criteria for Prospective Arm:~* Patients wishing to receive oral midazolam in a non-blinded fashion will not be excluded based on the size of an individual tumor, total number of tumors, or prior history of oral midazolam~* No upper weight limitation~Exclusion Criteria:~* Prior history of allergy to midazolam or any of the syrup components~* History of hypersensitivity to other benzodiazepines~* Congestive heart failure (AHA Class III and IV)~* Renal failure requiring hemodialysis~* End-stage liver failure~* Chronic alcoholism or alcohol intoxication within 24 hours of surgery~* Untreated or uncontrolled open angle glaucoma~* Uncontrolled hypertension~* History of psychoses or affective disorders~* Neuromuscular disorders such as myasthenia gravis~* Chronic obstructive pulmonary disease~* Patients on medications interfering with renal excretion or microsomal metabolism unless the last dose was taken greater than or equal to 5 half-lives prior to surgery~* Patients weighing less than 100 lb (45 kg)~* Pregnant women; women of childbearing potential will be required to take an in-office urine pregnancy test.~* Breast-feeding mothers must stop breast-feeding for 7 days after taking midazolam to take part in this study~Additional Exclusion Criteria for Randomized Arms:~* Patients with a single cancer \> 5 cm in the greatest dimension or with more than 2 cancers~* Patients who were previously premedicated with oral midazolam during prior Mohs micrographic surgery episodes~* Patients weighing more than 220 lb (100 kg)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Randomized Midazolam (Type: ACTIVE_COMPARATOR): Single-dose midazolam
- Placebo (Type: PLACEBO_COMPARATOR): None
- Prospective Midazolam (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).